Intraperitoneal injection of MSC-derived exosomes prevent experimental bronchopulmonary dysplasia

Area of Science:

• Regenerative Medicine
• Neonatal Physiology
• Pulmonary Biology

Background:

• Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants.
• Neonatal hyperoxia exposure causes lung injury, impairing alveolarization and angiogenesis.
• Mesenchymal stromal cell (MSC)-derived exosomes show therapeutic potential in tissue repair.

Purpose of the Study:

• To investigate the therapeutic effects of MSC-derived exosomes on hyperoxia-induced BPD in newborn rats.
• To evaluate the impact of exosome treatment on lung alveolarization, angiogenesis, and cardiac function.

Main Methods:

• Newborn rats were exposed to hyperoxia (85% O2) for 14 days to induce BPD.
• Daily intraperitoneal injections of MSC-derived exosomes were administered during hyperoxia.
• Lung histology, blood vessel density, and right heart hypertrophy were assessed at various time points (P14, P21, P56).
• In vitro studies assessed exosome effects on human umbilical vein endothelial cells (HUVECs) tube formation.

Main Results:

• Exosome treatment significantly protected alveolarization and increased angiogenesis in the BPD model.
• Treatment reduced right heart hypertrophy, a complication of BPD.
• In vitro, exosomes promoted HUVEC tube-like network formation, partly via VEGF.
• Exosomes demonstrated both anti-inflammatory and pro-angiogenic effects.

Conclusions:

• Daily intraperitoneal exosome administration effectively mitigates hyperoxia-induced lung injury and cardiac dysfunction in a BPD model.
• MSC-derived exosomes promote lung vascularization through pro-angiogenic mechanisms.
• These findings suggest MSC-derived exosomes are a promising therapeutic strategy for BPD and related lung diseases.